Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design

EGFR, epidermal growth factor receptor, protein tyrosine kinase, receptor tyrosine kinase, structure activity relationship, Anti-Cancer Agent, epidermal growth factor (EGF) receptors, protein tyrosine kinases, cancer therapy, monoclonal antibodies, cysteine-rich domains, α-and β-phosphates, DFG aspartate residue, DFG phenylalanine residue, Lapatinib, sorafenib, erlotinib, EGFR kinase, CDK2, transforming growth factor-α, amphiregulin, heparin-binding EGF, neuregulins, breast caner, mitogen-activated protein kinase (MAPK) pathway, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) pathway, signal transducer and activator of transcription (STAT) pathway, phospholipase C pathway and SRC/FAK pathway, avian erythroblastosis tumor, Autocrine-paracrine stimulation, umor necrosis factor-α(TGF-α), Cetuximab, Erbitux, Trastuzumab, Herceptin, Pertuzumab, Quinazoline Scaffold, Gefitinib, anilinoquinazoline scaffold, Alkynyl Pyrimidine Scaffold, Pyrrolotrizaine Scaff, Thiazolopyrimidine Scaffold, Quinoline-3-Carbonitrile Scaffold, Benzylidene Hydantoin Scaffold, 4-Amino-6-Arylaminopyrimidine-5-Carbaldehyde Oximes Scaffold, 4-Amino-6-Arylaminopyrimidine-5-Carbaldehyde Hydrazones Scaffold, 5-Oxadiazol-4,6-Diaminopyrimidines Scaffold, 5,7-Diazaindolinone Scaffold, Thiazolidinone Scaffold, Imidazothiazole Scaffold, Histone Deacetylases (HDACs), Pyrrolpyrimidine Scaffold, Acrylamide Scaffold, 1,2-Dithiolane Scaffold, Prrolidinyl-Acetylenicthienopyrimidine Scaffold